Amsterdam-based Leyden Labs, a platform working to free people from the threat of respiratory viruses has raised $70M (approximately €68M) in funding.
Leyden Laboratories B.V. (the "Company" or "Leyden Labs") today announced it has raised $70M in funding to advance its Mucosal Protection Platform. This non-vaccine approach utilizes broadly ...
Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback